Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver

Summary

This Huberman Lab episode has Andrew Huberman interview Craig Koniver about physician-supervised use of peptides, hormones, NAD, methylene blue, and related performance-medicine interventions. Its most transferable contribution is an evidence and safety boundary: regulated GLP-1 drugs must be distinguished from experimental compounds such as BPC-157, and clinical anecdotes about recovery, sleep, inflammation, cognition, or energy do not establish general efficacy. The episode repeatedly links possible benefit to individualized assessment, sourcing, sterility, dosing, monitoring, and legal access.

Key Claims

• Peptide Evidence Hierarchy is reinforced by the contrast between approved GLP-1 medicines, off-label prescribing, compounded preparations, experimental peptides, and research-only products.
• Koniver describes low-dose compounded semaglutide or tirzepatide as a way his clinic tries to slow weight loss and preserve lean mass, but the episode provides no controlled comparison establishing that protocol.
• BPC-157 is presented through broad clinical anecdotes about inflammation, soreness, tendon or ligament problems, gut issues, and recovery, while the episode acknowledges limited human trials.
• Peptide Sourcing Quality Risk includes identity, purity, sterility, endotoxin contamination, concentration, and the difference between supervised compounding and products labeled against human use.
• Growth Hormone Secretagogues are differentiated by claimed sleep, appetite, fat-loss, recovery, or endurance effects, but the account also includes variable response, PSA change, broad tissue-growth risk, and unresolved long-term outcomes.
• NAD Therapy Evidence Boundary separates reported improvements after intravenous or subcutaneous NAD from proof of antiviral, mood, cognitive, fatigue, addiction, or longevity efficacy.
• The episode treats sleep, exercise, nutrition, social connection, trust, and purpose as foundations that experimental tools may augment rather than replace.

Key Quotes

“not for human or animal use” — label language highlighted as a warning that a research product may not be prepared for injection.

Connections

• Huberman Lab, Andrew Huberman, and Craig Koniver - show, host, and guest context.
• Peptide Evidence Hierarchy, Regulated Peptide Access, Peptide Sourcing Quality Risk, Gray-Market Peptides, and Medical Risk Management - evidence, access, product-quality, and clinical-supervision frame.
• GLP-1 Agonists, GLP-1 Body Composition Stack, Lifestyle Weight Management / 生活方式体重管理, and Muscle As Longevity Infrastructure - metabolic treatment, weight-loss rate, lean-mass, and maintenance branch.
• BPC-157 Experimental Repair Peptide, Bioregulator Peptides, and Growth Hormone Secretagogues - experimental repair, sleep-peptide, and growth-hormone-adjacent branch.
• NAD Therapy Evidence Boundary, Mitochondrial Lifestyle Pillars, and Self-Experimentation - energy and mitochondrial claims bounded by anecdotal evidence and intervention risk.

Contradictions

• No settled contradiction found. The source’s favorable clinical anecdotes add practitioner experience but do not overturn the wiki’s distinction between biological plausibility, uncontrolled observation, and established human efficacy.
• The episode describes compounding pharmacies as regulated and tested, while existing pages note that compounding quality can vary; these claims are compatible when regulation is not treated as proof that every pharmacy, preparation, or protocol is equivalent.
• The source body repeatedly spells the guest’s surname “Conover,” while its metadata and episode title identify him as Craig Koniver; the canonical entity follows the metadata spelling.
• Dose schedules, inflammatory effects, REM-sleep changes, mitochondrial mechanisms, antiviral effects, detoxification claims, and patient outcomes remain source-scoped public medical discussion rather than individualized treatment guidance.